{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:44:54Z","timestamp":1790441094439,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"DOI":"10.7759\/cureus.106259","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:02:14Z","timestamp":1775037734000},"source":"Crossref","is-referenced-by-count":1,"title":["Early Evaluation of the Food and Drug Administration (FDA) Adverse Event Monitoring System (AEMS): An Analysis of Over 32 Million Pharmacovigilance Reports"],"prefix":"10.7759","author":[{"given":"Shaheen E","family":"Lakhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards IR","year":"2000","unstructured":"Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000, 356:1255-9. 10.1016\/S0140-6736(00)02799-9","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2007.124537","article-title":"Adverse event detection in drug development: recommendations and obligations beyond phase 3","volume":"98","author":"Berlin JA","year":"2008","unstructured":"Berlin JA, Glasser SC, Ellenberg SS. Adverse event detection in drug development: recommendations and obligations beyond phase 3. Am J Public Health. 2008, 98:1366-71. 10.2105\/AJPH.2007.124537","journal-title":"Am J Public Health"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda T","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2013, 10:796-803. 10.7150\/ijms.6048","journal-title":"Int J Med Sci"},{"key":"ref4","unstructured":"The global medicines safety database. (2026). Accessed. March 11, 2026: https:\/\/who-umc.org\/vigibase-data-access\/about-vigibase\/."},{"key":"ref5","unstructured":"EudraVigilance. (2026). Accessed. March 11, 2026: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/pharmacovigilance-research-development\/eu...."},{"key":"ref6","unstructured":"FDA launches new adverse event look-up tool. (2026). Accessed. March 11, 2026: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-launches-new-adverse-event-look-tool."},{"key":"ref7","unstructured":"FDA Adverse Event Monitoring System (AEMS) public dashboard. (2026). Accessed. March 11, 2026: https:\/\/www.fda.gov\/drugs\/fda-adverse-event-monitoring-system-aems\/fda-adverse-event-monitoring-system-aems-public-da...."},{"key":"ref8","unstructured":"openFDA. (2026). Accessed. March 11, 2026: https:\/\/open.fda.gov."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0494-6","article-title":"Women encounter ADRs more often than do men","volume":"64","author":"Zopf Y","year":"2008","unstructured":"Zopf Y, Rabe C, Neubert A, et al.. Women encounter ADRs more often than do men. Eur J Clin Pharmacol. 2008, 64:999-1004. 10.1007\/s00228-008-0494-6","journal-title":"Eur J Clin Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/187103","article-title":"Sex differences in drug disposition","volume":"2011","author":"Soldin OP","year":"2011","unstructured":"Soldin OP, Chung SH, Mattison DR. Sex differences in drug disposition. J Biomed Biotechnol. 2011, 2011:187103. 10.1155\/2011\/187103","journal-title":"J Biomed Biotechnol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200102060-00001","article-title":"Do women have more adverse drug reactions?","volume":"2","author":"Rademaker M","year":"2001","unstructured":"Rademaker M. Do women have more adverse drug reactions?. Am J Clin Dermatol. 2001, 2:349-51. 10.2165\/00128071-200102060-00001","journal-title":"Am J Clin Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell L","year":"2006","unstructured":"Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006, 29:385-96. 10.2165\/00002018-200629050-00003","journal-title":"Drug Saf"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528110-00002","article-title":"Perspectives on the use of data mining in pharmacovigilance","volume":"28","author":"Almenoff J","year":"2005","unstructured":"Almenoff J, Tonning JM, Gould AL, et al.. Perspectives on the use of data mining in pharmacovigilance. Drug Saf. 2005, 28:981-1007. 10.2165\/00002018-200528110-00002","journal-title":"Drug Saf"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate A","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009, 18:427-36. 10.1002\/pds.1742","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref15","unstructured":"Vaccine Adverse Event Reporting System. (2026). Accessed. March 11, 2026: https:\/\/vaers.hhs.gov."},{"key":"ref16","unstructured":"Manufacturer and User Facility Device Experience (MAUDE) database. (2026). Accessed. March 11, 2026: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfmaude\/search.cfm."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/476442-early-evaluation-of-the-food-and-drug-administration-fda-adverse-event-monitoring-system-aems-an-analysis-of-over-32-million-pharmacovigilance-reports","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:02:18Z","timestamp":1775037738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/476442-early-evaluation-of-the-food-and-drug-administration-fda-adverse-event-monitoring-system-aems-an-analysis-of-over-32-million-pharmacovigilance-reports"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.106259","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}